Luca Palmieri

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes.

Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes.

Journal: Gynecologic oncology

Published: June 19, 2026

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression.

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression.

Journal: Gynecologic oncology reports

Published: June 03, 2026

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Journal: Gynecologic oncology

Published: May 29, 2026

Ultrasound-First, Anatomy-Based Algorithm to Tailor the Extent of Hysterectomy in Placenta Accreta Spectrum.

Ultrasound-First, Anatomy-Based Algorithm to Tailor the Extent of Hysterectomy in Placenta Accreta Spectrum.

Journal: American journal of obstetrics & gynecology MFM

Published: May 04, 2026

Prognostic significance of lymphovascular space invasion extent across molecular classes in early-stage endometrial cancer: A large retrospective analysis.

Prognostic significance of lymphovascular space invasion extent across molecular classes in early-stage endometrial cancer: A large retrospective analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 12, 2026

Response regarding "Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using pre-clinical and clinical models" by Wu et al.

Response regarding "Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using pre-clinical and clinical models" by Wu et al.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 19, 2026

Integrated mutational landscape analysis of endometrial stromal sarcoma.

Integrated mutational landscape analysis of endometrial stromal sarcoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: January 27, 2026

Robotic secondary cytoreduction in recurrent ovarian cancer: a tailored approach for kidney transplant recipients.

Robotic secondary cytoreduction in recurrent ovarian cancer: a tailored approach for kidney transplant recipients.

Journal: Facts, views & vision in ObGyn

Published: December 08, 2025

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.

Journal: Gynecologic oncology

Published: December 02, 2025

Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma - A case report.

Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma - A case report.

Journal: Gynecologic oncology reports

Published: November 19, 2025

Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report.

Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report.

Journal: Cureus

Published: October 16, 2025

Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.

Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.

Journal: Gynecologic oncology

Published: August 23, 2025

Showing 1-12 of 31

Last Updated: 09/26/2026